# OnCo record brocade3 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/brocade3/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "brocade3", "NCT02163694" ;
  schema:name "BROCADE3"@en ;
  schema:description "BROCADE3 added the PARP inhibitor veliparib to carboplatin and paclitaxel for advanced breast cancer in women with an inherited BRCA mutation. It delayed progression by about two months but did not lengthen life, and the drug was never licensed; the long survival on chemotherapy alone showed how active platinum is in this group."@en ;
  schema:url <https://onco.cc/trials/brocade3/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02163694>, <https://doi.org/10.1016/S1470-2045(20)30447-2>, <https://doi.org/10.1016/j.ejca.2024.113580> ;
  onco:status "mixed" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-metastatic/>, <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/parp/>, <https://onco.cc/targets/brca/> ;
  onco:drugs <https://onco.cc/drugs/veliparib/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:companies <https://onco.cc/companies/abbvie/> ;
  onco:terms <https://onco.cc/terms/gbrca-mutation/> ;
  onco:trials <https://onco.cc/trials/olympiad/>, <https://onco.cc/trials/embraca/>, <https://onco.cc/trials/brightness/>, <https://onco.cc/trials/tnt/> .